Toulouse, France, October 2, 2008 - BT Pharma, a biopharmaceutical company developing innovative immunotherapies to treat diseases and cancer caused by the human papilloma virus (HPV), announces today the appointment of Prof. Thierry Hercend to the position of President of the Supervisory Board. (Variant of Board of Directors under French Law).
"Thierry Hercend has an outstanding international academic and industrial career. His appointment as president of our Supervisory Board will be of great value for BT Pharma as the company prepares the entry into clinical trials of ProCervix(R), our first candidate immunotherapeutic product," declared Benedikt Timmerman, Chief Executive Officer.
Dr Thierry Hercend, MD & PhD, has more than 30 years of academic and pharmaceutical experience in various therapeutic areas such as oncology and inflammatory diseases. Between 2002 and 2005, Thierry was Vice-President Oncology Research of Aventis. From 1998 to 2002, he was VP Research Europe at Vertex Pharmaceuticals. Previously, he was Head of R&D at LFB (Laboratoire Français du Fractionnement et des Biotechnologies). He also occupied several senior management functions at Roussel Uclaf. Before entering the pharmaceutical industry, Professor Thierry Hercend was Head of the Hematology and Immunology Laboratories at the Gustave Roussy Institute, Director of Research Unit INSERM 333 and Professor of Immunology at the Faculty of Medicine, Paris XI. He is author of over 120 scientific papers in Immunology, cancer and transplantation research. Currently, Thierry Hercend is a "Venture Partner" at Edmond de Rothschild Investment Partners (EdRIP) in Paris.
"BT Pharma is at the forefront of HPV R&D," said Prof. Hercend. "I look forward to contributing to the company's success in this field."
About BT Pharma S.A.
BT Pharma is a bio-pharmaceutical company that was spun out of the Institut Pasteur in 2002 and is currently based in Toulouse, France. The company develops immunotherapeutic products for the treatment of infection, neoplasia and cervical cancer caused by Human Papillomavirus (HPV). ProCervix(R), the company's most advanced product candidate is scheduled to enter into a phase 1 clinical trial in 2009. This bivalent therapeutic vaccine is designed to treat patients who are already infected with either one of the most frequent HPV genotypes: HPV16 and HPV18.
About the Human Papillomavirus (HPV)
Infection by HPV is the world's most common sexually transmitted viral disease affecting 400 million women each year. Of this population, 30 million have low grade cervical neoplasia while 10 million women carry dangerous high grade squamous intraepithelial cell lesions (HSIL), which contain cancer cells. Nearly 500,000 women will develop invasive cervical cancer. HPV16 et HPV18 are the viral genotypes that represent the highest risk of progression of HSIL lesions to invasive cancer and are the cause of cervical cancer in over 70 percent of cases. (WHO, September 2005)